Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder

International Journal of Urology

Volumn 4, Issue 6, 1997, Pages 561-565

  Ogura, Keiji ^a,c   Fukuzawa, Shigeki ^b   Habuchi, Tomonori ^c   Ogawa, Osamu ^c   Yoshida, Osamu ^c  

^a RAKUWAKAI OTOWA HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Nuclear morphometry; p53; PCNA

Indexed keywords

CYCLINE; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL TRIAL; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORPHOMETRICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; STEREOMETRY; TRANSITIONAL CELL CARCINOMA;

EID: 0031463523     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1997.tb00309.x     Document Type: Article

References (33)

1. Ooms ECM, Anderson WAD, Alons CL, Boon ME, Veldhuizen RW. Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol 1983;14:140-143.
2. Sørensen FB, Sasaki M, Fukuzawa S, Yamabe H, Olsen S, Yoshida O. Qualitative and quantitative histopathology in transional cell carcinomas of the urinary bladder: an international investigation of intra-and interobserver reproducibility. Lab Invest 1994;70:242-254
3. Parmar MKB, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial bladder cancer (Urological Cancer Working Party). J Urol 1989;142:284-288.
4. Diamond DA, Berry SJ, Jewett HJ, Eggleston JC, Coffy DS. A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. J Urol 1982;128:729-734.
5. Murphy GF, Partin AW, Maygarden SJ, Mohler JL. Nuclear shape analysis for assessment of prognosis in renal cell carcinoma. J Urol 1990;143:1103-1107.
6. Sorensen FB. Quantative analysis of nuclear size for objective malignancy grading: a review with emphasis on new unbiased stereologic method. Lab Invest 1992; 66:4-23.
7. Sasaki M, Sorensen FB, Fukuzawa S, Yamabe H, Olsen S, Yoshida O. Quantative histopathology in the prognostic evaluation of patients with transitional cell carcinoma of the urinary bladder. Cancer 1993;72:2470-2483.
8. Fukuzawa S, Hashimura T, Sasaki M, Yamabe H, Yoshida O. Nuclear morphometry for improved prediction of the prognosis of human bladder carcinoma. Cancer 1995;76: 1790-1796.
9. Tribukait B, Gustafson H, Esposti PL. The significance of ploidy and proliferation in the clinical and biological evaluation of bladder tumours. Br J Urol 1982;54:130-135.
10. Blomjous ECM, Schipper NW, Baak JPA, Vos W, de Voogt HJ, Meijer CJLM. The value of morphometry and DNA flow cytometry in additional to classic prognosticators in superficial urinary bladder carcinoma. Am J Clin Pathol 1989;91:243-248.
11. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA. Allelic loss of chromosome 9, 11, and 17 in human bladder cancer. Cancer Res 1990;50:44-47.
12. Habuchi T, Ogawa O, Kakehi Y, Ogura K, Koshiba M, Hamazaki S, Takahashi R, Sugiyama T, Yoshida O. Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer 1993;53:579-584.
13. Sidransky D, Eschenbach AV, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-709.
14. Habuchi T, Ogawa O, Kakehi Y, Ogura K, Koshiba M, Sugiyama T, Yoshida O. Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. J Urol 1993;148:1595-1599.
15. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S-C, Nichols PW, Skinner DG, Jones PA, Cote RJ. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1264.
16. Lipponen PK, Eskelinen MJ. Cell proliferation of transitional cell bladder tumours. Br J Cancer 1992;66:171-176.
17. Ogura K, Habuchi T, Yamada H, Ogawa O, Yoshida O. Immunohistochemical analysis of p53 and proliferative cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity. Int J Urol 1995;2: 302-308.
18. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. World Health Organization. Geneva, 1973.
19. Hermanek P, Sobin LH (eds). UICC (International Union Against Cancer):TNM classification of malignant tumours. 4th ed. Geneva; Springer-Verlag, 1987.
20. Banks L, Matlashewski G, Crawford L. Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159:529-534.
21. Reich NC, Levine AJ. Growth regulation of a cellular tumor antigen, p53, in nontransformed cells. Nature 1984;308:199-201.
22. Finlay CA, Hinds PW, Tan TH. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-539.
23. Cummings J. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992;52:1974-1980.
24. Esrig D, Spruck III CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen S-C, Skinner DG, Jones PA, Cote RJ. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-1397.
25. Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-294.
26. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991;51:4716-4720.
27. Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162:285-294.
28. Rathert R, Roth S, Soloway MS. Cytologic grading of urothelial tumors. In: Urinary cytology. New York: Springer-Verlag, 1993:53-59.
29. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. The cell nucleus. In: Molecular biology of the cell. New York: Garland Publishing, 1983:429-431.
30. Balska F, Barlow PW. The role of the microtublar cytoskeleton in determinating nuclear chromatin structure and passage of maize root cells through the cell cycle. Eur J Cell Biol 1993;61:160-167.
31. Levine AJ. p53 gene in protein. In: Mendelsohn J, Howley P, Israel MA, Liotta LA (eds) The molecular basis of cancer. Philadelphia: WB Saunders, 1995:94-98.
32. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990;62:671-680.
33. Martinez J, Georgoff I, Martinez J, Levine AJ. Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev 1991;5:151-159.